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Abstract
Background Paying pharmaceuticals out of pocket is an
important source of financing pharmaceutical consumption.
Only limited empirical knowledge is available on the
determinants of these expenditures.
Objectives In this article we analyze which characteristics
of private households influence out-of-pocket pharmaceu-
tical expenditure (OOPPE) in Austria.
Design and methods We use cross-sectional information
on OOPPE and household characteristics provided by the
Austrian household budget survey 2009/10. We split
pharmaceutical expenditures into the two components
prescription fees and over-the-counter (OTC) expenditures.
To adjust for the specific characteristics of the data, we
compare different econometric approaches: a two-part
model, hurdle model, generalized linear model and zero-
inflated negative binomial regression model.
Findings The finally selected econometric approaches give
a quite consistent picture. The probability of expenditures
of both types is strongly influenced by the household
structure. It increases with age, doctoral visits and the
presence of a female householder. The education level and
income only increase the probability of OTC pharmaceu-
ticals. The level of OTC expenditures remains widely
unexplained while the household structure and age influ-
ence the expenditures for prescription fees. Insurance
characteristics of private households, either private or
public, play a minor role in explaining the expenditure
levels in all specifications. This refers to a homogeneous
and comprehensive provision of pharmaceuticals in the
public part of the Austrian health care system.
Conclusions The article gives useful insights into the
determinants of pharmaceutical expenditures of private
households and supplements the previous research that
focuses on the individual level.
Keywords Out-of-pocket pharmaceutical expenditures 
Consumer survey  Two-part model  Generalized linear




Comparisons between OECD member states reveal that the
out-of-pocket share of total pharmaceutical spending (41 %
in 2011) is more than twice as much as the out-of-pocket
share of total spending on health services (18 % in 2011)
[1]. The empirical knowledge on the determinants of out-
of-pocket pharmaceutical expenditures (OOPPE) is lim-
ited. One reason for this fact is the lack of adequate routine
data on pharmaceutical expenditures on the individual and
household level. To understand the possible covariates
driving OOPPE and to select a sound econometric identi-
fication strategy require close insights into the interaction
between the relevant actors in the decision-making process
on pharmaceutical consumption. Such analyses end in
preferred specifications of indicators for pharmaceutical
use/expenditures and of possible influential covariates.
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provided by socioeconomic (e.g., SOEP in Germany) and
health-related surveys (NHANES in the US, EHES in
selected EU countries, ATHIS in Austria) fulfill such
claims only to a limited extent; specific information on
OOPPE is missing. In the following article we study the
determinants of OOPPE in Austria using cross-sectional
information from the latest national household budget
survey conducted in 2009/10 [2]. We give insights into the
socioeconomic determinants of OOPPE, an undertaking
that is new for pharmaceutical spending in Austria. The
article benefits from the voluminous previous research
work on out-of-pocket health-care expenditures based on
microdata in general [3–18] and on the scanty literature on
OOPPE and respectively on self-medication [19–25]. In the
following we briefly discuss the previous research work on
OOPPE and self-medication. In a two-part model, Lei-
bowitz et al. [21] study cost-sharing effects of prescription
drug expenditures using individual panel data from the
Rand Health Insurance Experiment. They find that drug
expenditures respond to the cost sharing faced by the
consumers. They also observe very significant site, age and
sex effects. Based on a cross-sectional data set on an
individual basis from Spain, Figueiras et al. [23] identify
sociodemographic factors associated with self-medication
(use of non-description drugs) using multivariate Cox’s
regression. They find that self-medication is more prevalent
among women, singles, persons living in large agglomer-
ations, and person with acute disorders and higher educa-
tion levels. Grootendorst [20] uses individual data from the
1990 Ontario Health Survey on the self-reported use of
prescription drugs to compare alternative econometric
models (Poisson model, negative binomial model, two part
models) to study the different determinants of drug use.
Chang/Trivedi [22] develop a theoretical model of self-
medication behavior of a utility-maximizing consumer.
Empirically, they especially focus on the role of income
and health insurance on self-medication. Chan/Trivedi use
individual cross-sectional data from the World Bank’s
Living Standards Measurement Survey of Vietnam
1997–1998 and apply an econometric framework similar to
[20]. They find that self-medication is an inferior good at
high income levels and a normal good at low income
levels. Insurance coverage strongly reduces self-medica-
tion. Costa-Font et al. [19] study the determinants of drug
consumption in Catalonia using official survey data on an
individual basis. Econometrically, a two-part model is
used. They find evidence that gender, health status and the
existence of insurance are significant predictors for out-of-
pocket pharmaceutical expenditures. Income and cost
sharing are strongly associated with drug use but not drug
expenditures. McLeod et al. [24] analyze the financial
burden of out-of-pocket expenditures for prescription drugs
based on cross-sectional national survey data from Canada.
They focus on the household drug budget share and esti-
mate Engle curves for different drug budget shares using
predicted values from the kernel conditional quantile esti-
mator. Tavares [25] derives a formal model of self-medi-
cation based on the maximization of a utility function that
depends on consumption and on health status. Thereby
Tavares especially focuses on the role of time. Individual
data from the Portuguese 4th National Health Survey
(2005) are used in a probit model with self-medication as a
binary variable. The results show significant effects for age
and gender. As far as waiting time is concerned, Tavares
offers mixed results.
Summarizing these studies we observe important dif-
ferences in the study designs, the data used and the
observed results. The majority of the studies are based on
individual data; only [24] uses data from the household
level. All studies using individual data except [21] directly
control for the individual health status. Reports [22] and
[25] base their empirical estimation on a theoretical model
of drug consumption (self-medication), while the other
papers use different steps of reduced forms. Reports [20–
22] use two-part models in the econometric specification.
Thereby, [20] and to some extent [22] present a detailed
comparison and discussion of alternative model specifica-
tions. The clear focus of [19, 21] is price effects on the
pharmaceutical consumption measured by the level of
insurance coverage.
Our article contributes to the empirical research on
OOPPE in several ways. First, it adds evidence from the
perspective of the household and supplements the findings
available from the individual level in the previous litera-
ture. Second, we use data from a health-care system that is
based on Bismarckian principles and that holds a specific
two-tiered institutional architecture of service provision
and financing. Third, we keep in mind households’ deci-
sion-making process of either seeking professional health
care or using self-medication, which leads to three types of
out-of-pocket expenditures. We account for this fact by
separating the available database into subgroups to analyze
the different types of OOPPE separately. Finally, our
source of information is the general household budget
survey, while previous studies build on health-related sur-
veys. Since national household budget surveys follow
internationally agreed principals, our study also allows
conclusions on whether budget surveys are an appropriate
database to analyze the determinants of out-of-pocket
health-care expenditures.
The remainder of the article is organized as follows. In
‘‘The policy setting of pharmaceutical consumption in
Austria,’’ we present a brief overview of the main institu-
tional characteristics of consuming pharmaceuticals in
Austria. In ‘‘Databases and empirical approach,’’ we
inform about the databases and derive conclusions for the
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empirical approach applied in the article. In ‘‘Econometric
results and discussion,’’ we present the empirical results
and discuss them. In ‘‘Conclusions,’’ we conclude our
article.
The policy setting of pharmaceutical consumption
in Austria
In Austria authorities of the central state regulate basic
dimensions of pharmaceutical consumption. They decide on
the general preconditions and modes of market entry of
pharmaceuticals, specifically on the separation between
pharmaceuticals with obligatory prescription (8.026 phar-
maceuticals in 2012; [26]) and over-the-counter (OTC)
products (1.931 pharmaceuticals in 2012; [26]) and on phar-
maceutical pricing.Thereby, the regulation ofprices primarily
focuses onmaximumpricemargins of thewholesale firms and
pharmacies,while factory prices are not regulated inAustria at
this stage [27]. But this general regulation ofmarket entry and
prices primarily influences the provision of pharmaceuticals
paid over the counter. There exists a second stage of public
regulation ofmarket entry and pricing conducted by the social
health insurance system. Since social health insurance in
Austria covers around 99.3 % of the whole population—ex-
cluding only marginal groups from public health insurance—
this regulation has far-reaching consequences for pharma-
ceutical pricing and consumption [28].1Only pharmaceuticals
included in the positive list of the Reimbursement Code are
paid by the social health insurance system. Thereby, the
Reimbursement Code includes pharmaceuticals with and
without obligatory prescription [29].2
Pharmaceuticals that are part of inpatient treatments are
free for patients with social health insurance coverage. Their
costs are included in the DRG-based hospital remuneration
system [29, 30]. Pharmaceuticals that are part of outpatient
treatments provided by GPs/specialists having a contract
with the social health insurance system are basically free if
they are included in the positive list of the Reimbursement
Code. Patients have to pay a prescription fee for every
pharmaceutical prescribed. This prescription fee is an
absolute amount of money (in the years of the household
survey: 2009: €4.90, 2010: €5.00) with no link to the price of
the pharmaceutical. If the price of the pharmaceutical is
below the prescription fee, patients only have to pay the price
of the pharmaceutical. Calculated over the total range of
pharmaceutical consumption financed by the social health
insurance system, the prescription fee leads to a cost sharing
of approximately 13 % [31]. If patients consume medical
services supplied by private doctors, pharmaceuticals are
paid by the social insurance system on request.
As far as the prescription fees are concerned, two schemes
influence the financial burden of individuals (households). An
exemption exists from the prescription fee and a prescription
fee cap. An exemption is granted without application (1) for
retired persons who draw a small pension from a public pen-
sion plan, (2) for persons with notifiable communicable dis-
eases, (3) for members of the alternative civilian service
including their relatives and (4) for asylum seekers. On
application, an exemption from the prescription fee is granted
for insurance members (including co-insured household
members) with a household net income below the threshold
value of the basic incomemaintenance system. Since 2008 the
exemption from the prescription fee is accompanied by a
prescription fee cap at a 2 % share of the annual net income.
Roughly 35 %3 of the population has signed contracts
with private sickness funds, which predominantly offer
additional coverage to services of the social health insur-
ance system and/or improve the possibility to choose from
a broader portfolio of providers/services within the system.
But private health insurance does not play a significant role
in financing pharmaceutical consumption. Only 0.2 % of
the prescribed drugs and 1.7 % of the OTC products were
paid by the private health insurance system in 2012 [33].
Having in mind the institutional setting of consuming
pharmaceuticals in Austria, we are able to identify possible
treatment paths in the health care sector that might lead to
OOPPE (see Fig. 1). In the first step the patient has to
decide whether to rely on self-medication or to seek pro-
fessional health care [22, 25]. In Austria, self-medication
accounts for approximately 20 % of total pharmaceutical
consumption (outside the hospital) and is mainly financed
out of pocket [27]. If the patient decides to use outpatient
medical services, pharmaceuticals with and without obli-
gatory prescription are consumed. If they are funded by the
social health insurance system, the patient only has to pay
the prescription fee. If they are not funded, the patient has
to pay the price. On average, 80 % of the pharmaceutical
consumption (outside the hospital) in Austria is based on a
1 Thereby, the public health insurance consists of different sickness
funds. They are separated by territorial and occupational character-
istics and have restricted autonomy in defining the terms of
consumption of publicly paid health-care services. Workers in the
private sector (76 % of the population) are covered by nine sickness
funds operating at the level of the nine provinces (named GKK in our
tables later on). Farmers (4 %; sickness fund named SVB), employers
(8 %; sickness fund named SVA) and public workers (8 %; sickness
fund named BVA) are covered by nationwide operating insurance
institutions.
2 In 2009 the total expenditures for pharmaceuticals without obliga-
tory prescription amounted to 526 million euros [12 % of the total
pharmaceutical market (hospitals excluded)]. Eight percent of the
expenditures for these products is refunded by the social health
insurance system [27].
3 Information from 2012; for details, see Versicherungsverband
O¨sterreich [32].
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prescription, 88 % of this consumption is refinanced by the
social health insurance system, 11.8 % is paid out of
pocket, and 0.2 % is refinanced by private sickness funds
[33]. Summarizing, we end up with three forms of OOPPE
(see Fig. 1): (1) OOPPE as a consequence of self-medi-
cation (OOPPE type 1); (2) OOPPE as a consequence of
consulting the professional outpatient health-care sector
and consuming pharmaceuticals that are not included in the
Reimbursement Code of the social health insurance system
(OOPPE type 2); (3) prescription fees for pharmaceuticals
prescribed by the outpatient health care sector and paid by
the social health insurance system (OOPPE type 3).
Databases and empirical approach
Databases
To analyze the socioeconomic determinants of OOPPE
empirically, we use data from the household budget survey
2009/10 conducted by Statistics Austria. This periodically
repeated survey is used to study the level and structure of
private consumption of households within the System of
National Accounts. The observation unit is the private
household without institutionalized households. The total
sample offered by Statistics Austria consists of 6534
households with 15,540 members. We exclude 747
households with unclear household and/or social health
insurance status and use a final sample size of 5787
households.4
Information on the consumption behavior is gathered in
two ways: (1) the diary approach and (2) the recall approach.
Households participating in the survey are asked to fill in a
diary over 14 days. The system results in 52 overlapping
weeks of bookkeeping. The recall approach is used for
consumer durables and irregular/seasonal expenditures
within the last 12 months. Selected socioeconomic charac-
teristics of the household are gathered by face-to-face
interviews. All expenditures are recalculated into monthly
expenditures. Following the expenditure classification of the
household budget survey, pharmaceutical expenditures are
included in the expenditure category ‘‘pharmaceuticals and
medical products.’’ We only focus on pharmaceuticals here,
thereby excluding dietary supplements. The subcategory
‘‘pharmaceuticals’’ is only separated into pharmaceuticals
paid over the counter (OOPPE type 1 and 2) and prescription
fees (OOPPE type 3). This inseparability of OOPPE of type 1
and 2 is an obvious backlash of our data set since self-med-
ication—resulting in OOPPE of type 1 (Fig. 1)—is expected
to be influenced by different covariates compared to the
consumption of pharmaceuticals, resulting inOOPPEof type
2 (for economic models of self-medication, see [22, 23, 25]).
The aggregation of the monetary consequences of the two
different treatment paths blasts information. From the sys-
tem of health accounts, we are able to conclude, that on
average more than 80 % of the pharmaceutical expenditures
paid over the counter result from the treatment path self-
medication (OOPPE of type 1), but there is no guarantee that
this share is unaffected by household characteristics [33].
Empirical approach
For econometric and economic reasons, hurdle models,
specifically two-part models, serve as methodological
Fig. 1 Utilization decision and types of OOPPE
4 No direct information on the public health insurance status of
household members is provided in the household survey. We derive
the insurance status from occupational characteristics of the house-
hold members. This might lead to minor blurring.
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cornerstones to explain health-care utilization/expenditures
[8, 13, 21]. The first part is a binary model that focuses on
the separation between use (rs) and nonuse (rs). The second
part explains the level/frequency of medical care use
conditional on some use. Statistically, the split in the
estimation procedure is substantiated by three specific
characteristics of health-care utilization/expenditures and
their consequences for the efficiency of estimation: (1)
skewness, (2) excess zeros and (3) heavy right tails. From
an economic perspective, the split in the estimation pro-
cedure is motivated by the fact that the two decision stages
are characterized by differences of the involved decision
makers. Thereby, the empirical strategy in the first step is
in general based on structural or reduced-form equations of
the Grossman model of demand for health services [34,
35]. The patient seeking care decides autonomously whe-
ther to seek professional diagnostic and curative medical
help at all. The modeling of the second step is guided by
principle-agent considerations leading to joint decisions of
patients and their health-care suppliers.
In a nutshell, the ideal starting point of two-part models
is the episode of medical treatment defined as a set of
medical services received continuously by a patient in
response to particular requests caused by a specific illness
(for an extended discussion, see [15]). Thereby, the first
step pictures a patient’s contact with medical providers,
called the illness spell. The second step includes the result
of the joint decisions captured by indicators such as health
expenditures, treatment visits, referrals and prescriptions. It
is obvious that the standards of data collection that enable
us to differentiate between these two steps are challenging
and hardly ever fulfilled by routine data. The previous
literature is only partially aware of this fact in the choice of
the empirical strategy [13, 20]. Only Santos Silvia and
Windmeijer give a profound discussion of this problem and
offer solutions for count data (physician visits) if the mix of
the initial treatment spell and the following visits is not
identifiable in the data set [14]. The description of the data
processing for OOPPE in Austria makes clear that our data
set does not perfectly fulfill the ideal preconditions for
using a two-part model for several reasons. Basically, we
have pharmaceutical expenditure data of a household
gathered in a short observation period of 2 weeks. This
observation period coincides with the length of an illness
episode only by chance. The episode might start before the
observation period and/or last longer and might lead to left
and/or right truncation as a consequence. There is no
possibility to separate between the initial spell and the
following treatment contacts. The only information avail-
able is expenditure levels in a time period without knowing
the number of contacts. These identification problems are
multiplied by the fact that we observe OOPPE on the
household level only. The same level of OOPPE is
compatible with different utilization patterns of the single
household members. Finally, the decision process leading
to OOPPE and specifically the interaction of the two
decision steps differ between the different types of OOPPE.
Taking into account these characteristics of our data set,
the structural appeal of the two-part model is less obvious.
We react to this fact and use different econometric
approaches. In the case of OTC pharmaceuticals (OOPPE
type 1 and 2), we apply a two-part model (TPM) and a one-
stage generalized linear model (GLM). Considering the
TPM, the first stage of the model predicts the likelihood of
any OOPPE and was specified as Logit. The second part
predicts the level of spending, conditional on having non-
zero OOPPE. As an alternative modeling strategy, we use a
GLM that estimates the parameters of the two processes
jointly. To specify the GLM models. we proceed in the
following way: We test for the kurtosis of the log-trans-
formed OOPPE to determine the link function. Following
the literature, the relationship between the variance and the
mean is estimated by a modified Park test [36]. In this
procedure, the squared residuals from a provisional log-
transformed OLS model or a provisional GLM model are
regressed on the predictions from the same model. The
corresponding coefficient suggests either a constant vari-
ance model (k = 0), a model whose variance is propor-
tional to the mean (k = 1), or the standard deviation
proportional to the mean model (k = 2). However, the best
model specification falls typically between the two latter
models. The performance of the chosen model will be
evaluated by computing the mean absolute error, mean
squared error and R2 scores as suggested by Matsaganis
et al. [11]. For both econometric approaches, we further use
Pregibon’s Link test, Ramsey’s Reset test, a modified
Hosmer-Lemeshow test, Cook’s distance and an overall
goodness of fit test for the combined model to evaluate the
fit of the chosen model.
In the case of prescription fees (OOPPE type 3), we
recalculated the non-zero expenditures into the number of
prescriptions by the application of prescription fee inter-
vals. So our variable ‘‘prescription fees’’ pictures at once
the household expenditures for prescription fees and the
consumption of publicly financed pharmaceuticals. To deal
with the distribution of the data, the high frequency and the
expected heterogeneity (the different sources) of the zeros,
we test several regression models: Poisson, a negative
binomial model (NB), a zero-inflated negative binomial
model (ZINB) and a hurdle model (two-part model for
count data) (for a detailed discussion, see [20]). The
goodness of fit of the corresponding models was evaluated
by using the likelihood-ratio test to compare Poisson vs.
NB and the (ZIP) vs. (ZINB). We further used the BIC and
AIC statistics (Poisson vs. NB/ZIP/ZINB, NB vs. ZIP/
ZINB and ZIP/ZINB) and the Vuong test (Poisson vs. ZIP,
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NB vs. ZINB, ZIP vs. ZINB) as well as the mean absolute
error and mean squared error as model selection criteria as
recommended in the literature [20, 37]. In contrast, in the
hurdle model it is assumed that all zeros are from one
source and that the non-zero part of the data follows a
truncated Poisson or a truncated negative binomial distri-
bution [37]. The model comparison of this positive part is
undertaken by the likelihood ratio test, while the latter
goodness of fit test encompasses Pregibon’s Link test and
Ramsey’s Reset test.
No explicit behavioral model of OOPPE is put forward;
in fact, a reduced form model is estimated. We extensively
test for the household structure, which captures not only the
size and composition of the household, but to some extent
also pictures different phases in the lifecycle of a house-
hold (single, unmarried couple, married couple, full nest I,
full nest II, empty nest). We further control for adults’ age,
adults’ education level, household income, gender of the
householders, the existence of early retirement individuals
in the household and the socioeconomic surrounding of the
household expressed by the degree of urbanization. In
addition, we also test whether the type of public health
insurance and the existence of private health insurances
influence the OOPPE. Finally, we control for doctoral visits
by any household member indicated by the out-of-pocket
expenditures for physician services in the observation
period and defined as dummy variables. Hereby, doctoral
visits can be considered as a proxy for the low health status
of at least one household member. We expect a positive
effect on OOPPE, because physician contacts could be an
indicator for a low health status and therefore might
increase the demand for pharmaceuticals. Table 4 (in the
‘‘Appendix’’) contains the detailed description of the
variables employed in the study.
Econometric results and discussion
Table 1 shows the descriptive statistics of the explanatory
variables. Out of 5787 households, 1150 have non-zero
expenditures for prescription fees with a mean per month
of 34.47. In the case of OTC pharmaceuticals, the non-zero
mean expenditures of the 1559 households sum up to
41.00. In the raw data, we observe substantial differences
of OOPPE levels depending on the household structure,
adults’ age, adults’ education level and the type of public
health insurance. The differences are more pronounced for
OTC pharmaceuticals compared to prescription fees.
Table 2 shows the econometric results of the TPM and
GLM for OTC pharmaceuticals (OOPPE type 1 and 2). The
probability for OTC spending is strongly influenced by the
life cycle of the household. The signs of the coefficients are
highly plausible; the size of the coefficients are partially
unexpected. There is some evidence that the probability of
OTC spending is lower in regions with a low degree of
urbanization. As far as self-medication is concerned, the
difference in the relative time costs of using professional
health services compared to pharmacies could be an impor-
tant covariate to explain this fact [22], but our data do not
allow to test for this hypothesis. The positive relationship of
the OTC spending with age—especially in the older age
groups 45–65 and[65—is expected andwell documented in
previous empirical research. The education level increases
the probability for OTC spending significantly. The health
insurance characteristics of the household—either private or
public—are of very limited influence on probability of OTC
spending. This follows our expectations for several reasons.
The general preconditions of consuming pharmaceuticals
(e.g., pharmaceuticals included in the positive list, level of
the prescription fee, exemptions from the prescription fee) do
not differ among the different public sickness funds (GKK,
BVA, SVA, SVB) compared in the sample. Differences
might be caused only indirectly by differences in the
socioeconomic characteristics of the different groups of
publicly insured (e.g., opportunity costs of time when being
ill, schedules of physician services remuneration). As
already mentioned, private health insurance only plays a
very limited role in financing pharmaceutical consumption
in Austria. So we expect only indirect effects on the OOPPE-
levels caused by, e.g., higher risk aversion of individuals
with private health insurance or effects of the remuneration
system of private health insurance on treatment behavior of
health-care providers. Household income and female gender
of the householder increases the probability of positive OTC
spending. Finally, we observe that doctoral visits of a
household member in the same period increase the possi-
bility ofOTCexpenditures.According to theBox-Cox test (k
near zero), we use for the second stage an OLS model with a
log-transformed dependent variable denoted as log OLS in
Table 2. In contrast to the highly significant covariates of the
first stage, the covariates of the second stage remain largely
insignificant. The income elasticity of OTC expenditures is
near zero (0.073), but the coefficient is insignificant. One
interpretation of the results on the second stage could be that
the probability of OTC consumption of a household sys-
tematically depends on several household characteristics,
while the level of expenditures is highly stochastic in the
short time perspective represented in our data.
Columns 5 and 6 of Table 2 show the results of the
GLM. We tested for the kurtosis of the log-transformed
OOPPE that takes the value 2.99, which is very close to 3
and therefore justifies a log link function. As mentioned
in the empirical approach, we performed a modified Park
test. The corresponding estimates are k = 1.55 (provi-
sional OLS model with log-transformed dependent vari-
able) and k = 1.20 (provisional GLM model) favoring a
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variance proportional to the mean model. In the evalua-
tion of the model performance, the variance proportional
to the mean model clearly outperforms the alternative.5
We used this specification in our estimation. Our results
reveal a significant effect of the household structure,
adults’ age, adults’ education level and doctoral visits.
The same is true with restrictions for the degree of
urbanization. Income remains insignificant, which is also
true for private and public insurance characteristics (ex-
emption: BVA). Considering both model specifications
for the analysis of OTC pharmaceuticals, the one-stage
GLM predominately approves the findings of the TPM
except for household income and the status of early
retirement.
Table 3 shows the econometric results for the second
form of OOPPE—the prescription fees (OOPPE type 3).
We compared the performance of different econometric
Table 1 Descriptive statistics
of the variables employed
according to both types of
OOPPE
Total households Prescription fees OTC pharmaceuticals
Average exp. Exp.[0 Average exp. Exp.[0
Mean SD Mean SD Mean SD Mean SD
Household structure
Single person I 3.39 12.76 30.30 25.43 6.86 26.12 41.87 52.10
Single person II 5.97 15.72 30.69 22.65 7.53 25.49 35.52 45.60
Unmarried couple 4.20 15.45 33.52 30.63 13.66 31.10 48.32 41.88
Married couple 8.07 23.84 37.82 39.33 9.99 25.56 38.27 37.77
Empty nest 4.14 11.83 24.51 18.18 14.69 36.72 42.24 52.15
Full nest I 5.65 18.49 27.48 32.67 13.63 34.79 42.49 50.51
Full nest II 17.67 32.44 47.80 37.53 13.27 35.53 42.76 53.05
Married couple w/o childs 6.58 15.42 28.54 20.18 12.84 34.25 41.65 51.15
Single parents 2.41 9.08 24.12 17.52 9.57 24.68 37.38 36.70
Degree of urbanization
High urbanization 6.69 20.82 36.01 35.77 11.55 31.35 42.48 47.99
Average urbanization 7.43 20.88 35.71 32.96 11.13 28.00 38.72 40.76
Low urbanization 6.61 17.63 32.32 26.25 10.52 32.34 41.29 53.27
Adults’ age structure
Age\25 1.31 6.15 21.05 14.25 6.11 21.80 43.84 42.44
Age 25–45 3.10 10.55 23.74 19.05 11.98 32.86 43.32 50.49
Age 45–65 7.37 20.88 34.15 33.27 10.29 28.10 38.50 43.26
Age 65–85 14.09 28.31 43.87 34.49 11.68 33.66 41.16 52.77
Adults’ education level
Primary education 7.64 19.71 37.79 28.03 5.91 18.66 34.05 32.43
Other education 7.04 19.86 34.21 31.43 11.49 32.01 41.09 49.50
Tertiary education 4.04 17.57 30.79 39.38 14.55 34.20 45.90 47.52
Insurance characteristics
GKK 6.66 19.21 34.04 30.90 10.05 29.15 39.08 46.61
BVA 7.61 20.13 34.73 30.154 15.17 37.27 45.59 52.85
SVA 6.76 22.94 37.16 42.18 12.01 32.67 45.77 50.34
SVB 6.82 17.31 36.02 23.18 6.62 18.28 34.96 28.06
Private health insurancea 8.30 23.98 36.68 38.82 13.38 33.29 42.21 47.80
Private health insuranceb 7.62 20.83 35.61 32.15 12.62 35.40 42.53 54.36
Total households 6.85 19.67 34.47 31.54 11.05 30.91 41.00 48.16
N (households) 5787 1150 5787 1559
a Corresponds to one adult of the household who has an additional private health insurance
b Corresponds to both adults of the households that have an additional private health insurance. This also
includes households consisting of one individual (single person I and single person II). Dummy variables
for female householders and income are not reported in the table. For definitions of the particular variables
employed, see Table 4 in the ‘‘Appendix’’
5 According to the results of Cook’s distance, we excluded 12
observations and based our findings of the GLM on 5775 households.
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models using likelihood ratio tests, BIC, AIC and Vuong
tests as model selection criteria. The zero inflated negative
binomial model (ZINB) fits better than all other models.
This is also true for the NB in the positive part of the hurdle
model. Therefore, Table 3 only presents the results for the
hurdle model—with the NB specification in the first step—
and the ZINB model when focusing on the characteristics
of the zeros.
The results of the hurdle model are shown in the left part
of Table 3. The first part of the model is defined as logit
and demonstrates the importance of the households’ life
cycle. Especially households consisting of more household
Table 2 Econometric results of
the two-part model and GLM
for OTC pharmaceuticals
Two-part model GLMb
Logit Conditional (log OLS)a
Coeff. Rob. SD Coeff. Rob. SD Coeff. Rob. SD
Household structure
Single person II -0.055 0.165 -0.046 0.112 -0.059 0.171
Unmarried couple 0.636*** 0.196 0.201 0.130 0.741*** 0.194
Married couple 0.365** 0.180 0.007 0.121 0.393** 0.196
Empty nest 1.094*** 0.171 -0.003 0.115 0.425** 0.196
Full nest I 0.790*** 0.170 0.027 0.114 0.845*** 0.175
Full nest II 0.417** 0.191 0.061 0.120 0.737*** 0.188
Married couple w/o childs 0.762*** 0.205 0.010 0.137 0.652*** 0.211
Single parents 0.373** 0.177 -0.029 0.120 0.302 0.209
Degree of urbanization
Average urbanization 0.088 0.092 -0.065 0.060 -0.054 0.090
Low urbanization -0.159* 0.087 -0.062 0.057 -0.170* 0.093
Adults’ age structure
Age 25–45 0.337 0.256 -0.088 0.177 0.413 0.256
Age 45–65 0.555** 0.262 -0.196 0.182 0.467* 0.267
Age 65–85 0.935*** 0.283 -0.148 0.191 0.817*** 0.276
Adults’ education level
Other education 0.473*** 0.137 0.022 0.091 0.503*** 0.143
Tertiary education 0.697*** 0.186 0.123 0.119 0.702*** 0.185
Insurance characteristics
BVA 0.181** 0.091 0.094 0.059 0.206** 0.087
SVA -0.087 0.132 0.147* 0.087 0.129 0.160
SVB -0.257 0.238 0.097 0.167 -0.179 0.245
Private health insurancec -0.029 0.109 -0.042 0.072 -0.023 0.112
Private health insuranced 0.074 0.089 0.008 0.059 0.044 0.103
Other characteristics
Early retired -0.142 0.158 0.012 0.107 -0.326** 0.156
Female householder 0.264*** 0.092 0.004 0.063 0.195* 0.103
Doctoral visits 0.367*** 0.108 0.061 0.068 0.346*** 0.010
Income (log) 0.188** 0.090 0.073 0.062 0.138 0.092
Constant -4.035*** 0.704 2.780*** 0.486 -0.258 0.720
Observations (households) 5787 1559 5775
a Log-transformed dependent variable
b GLM with log-link and Poisson distribution
c Corresponds to one adult of the household who has an additional private health insurance
d All adults of the household have an additional health insurance. This also includes households consisting
of one individual (single person I and single person II). Reference groups: single person I, high urban-
ization, age class 18 - 25, primary education, GKK, no additional private health insurance, male house-
holder, not early retired and no doctoral visit
Significance level: *** p\ 0.01, ** p\ 0.05, * p\ 0.1
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members (married couples, empty nest, full nest I and full
nest II) increase the probability of having prescriptions
significantly. Surprisingly, single parents have a signifi-
cantly lower probability of non-zero prescriptions. Adults’
increased age (age groups 45–65 and 65–85), female
householders and doctoral visits within the observation
period increase the probability, while early retired house-
holders and households who are insured at SVA decrease it
significantly. The existence of private health insurance,
income, education and the degree of urbanization have no
effect on the probability of prescriptions. The second part
of the model is defined as zero-truncated Poisson
Table 3 Econometric results of the hurdle model and zero-inflated negative binomial regression model for prescription fees
Hurdle model Zero-inflated negative binomial
Logit Negative binomial Logit Negative binomial
Coeff. Rob. SD Coeff. Rob. SD Coeff. Rob. SD Coeff. Rob. SD
Household structure
Single person II -0.062 0.190 -0.023 0.141 0.072 0.211 -0.010 0.137
Unmarried couple -0.154 0.245 0.392* 0.217 0.302 0.273 0.393* 0.215
Married couple 0.368* 0.203 0.489*** 0.177 -0.217 0.227 0.501*** 0.176
Empty nest 0.651*** 0.199 0.577*** 0.156 -0.504** 0.222 0.597*** 0.155
Full nest I 0.632*** 0.204 0.235 0.190 -0.581** 0.250 0.242 0.200
Full nest II 0.472** 0.196 0.154 0.174 -0.439* 0.232 0.172 0.180
Married couple w/o childs 0.336 0.234 0.071 0.178 -0.333 0.268 0.079 0.176
Single parents -0.459* 0.243 0.027 0.202 0.498* 0.278 0.055 0.204
Degree of urbanization
Average urbanization -0.012 0.103 -0.019 0.082 0.000 0.115 -0.030 0.082
Low urbanization -0.133 0.096 -0.131 0.081 0.083 0.107 -0.145* 0.083
Adults’ age structure
Age 25–45 0.599 0.375 0.434 0.304 -0.426 0.468 0.431 0.294
Age 45–65 1.283*** 0.378 0.804** 0.318 -1.011** 0.474 0.793** 0.312
Age 65–85 1.850*** 0.392 0.948*** 0.325 -1.564*** 0.487 0.939*** 0.319
Adults’ education level
Other education 0.136 0.134 -0.066 0.090 -0.163 0.144 -0.067 0.089
Tertiary education -0.260 0.218 0.127 0.179 0.327 0.234 0.134 0.181
Insurance characteristics
BVA -0.094 0.109 -0.017 0.082 0.095 0.120 -0.010 0.082
SVA -0.264* 0.154 -0.041 0.136 0.278 0.173 -0.021 0.135
SVB -0.263 0.253 0.066 0.166 0.308 0.270 0.101 0.163
Private health insurancea 0.087 0.125 -0.047 0.108 -0.120 0.145 -0.053 0.110
Private health insuranceb 0.061 0.101 0.067 0.078 -0.048 0.114 0.060 0.080
Other characteristics
Early retired -0.313* 0.181 0.157 0.149 0.370* 0.190 0.159 0.148
Female householder 0.183* 0.107 -0.051 0.096 -0.212* 0.120 -0.048 0.090
Doctoral visits 0.446*** 0.121 -0.160* 0.093 -0.558*** 0.144 -0.173* 0.095
Income (log) 0.099 0.108 -0.146* 0.080 -0.161 0.121 -0.154* 0.082
Constant -3.734*** 0.873 1.303** 0.648 3.725*** 0.984 1.366** 0.643
Observations (households) 5787 1150 5787
Lna -0.938*** 0.141
a 0.392 0.055
a Corresponds to one adult of the household who has an additional private health insurance
b All adults of the household have an additional private health insurance. This also includes households consisting of one individual (single
person I and single person II). Reference groups: single person I, high urbanization, age class 18–25, primary education, GKK, no additional
private health insurance, male householder, not early retired and no doctoral visit
Significance level: *** p\ 0.01, ** p\ 0.05, * p\ 0.1
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regression. Concerning the household structure, the results
show that the log count of prescriptions increases signifi-
cantly for unmarried and married couples, empty nests and
adults with increased age (age groups 45–65 and 65–85)
and decreases with income and doctoral visits of the
affected household members.
The right part of Table 3 shows the results of the ZINB
regression model. The splitting function (logit) reveals the
covariates that influence the probabilities of true zeros. As
expected, the coefficients of the covariates show a similar
size but reversed signs compared with the first step of the
hurdle model: e.g., the probability of a true zero in the
prescription variable strongly decreases with age. Addi-
tionally, the existence of doctoral visits, female house-
holders and children (full nest I, full nest II) decreases the
probability of true zeros. In contrast, single parents and
householders who are early retired increase the log odds of
true zeros. The level of prescriptions (NB) sharply
increases with age, is inverse to the degree of urbanization
and decreases with income. The expected number of pre-
scriptions for unmarried couples is 1.48 times the expected
number of prescriptions for a single person I while holding
all other variables constant. Furthermore, married couples,
empty nests and households without doctoral visits in the
observed time period have a higher expected number of
prescriptions than the particular reference groups (see
column 5 and 6 of Table 3). Public insurance characteris-
tics and the existence of private health insurance remain
insignificant in both estimation stages. The same is true for
the level of education. Using AIC, we also tested the hurdle
model and ZINB model [37] and found a better model fit
for the ZINB model.
Our study differs from the previous research in several
respects. We use data from the household level, while the
majority of the previous studies use individual data. Our
study analyzes two different forms of OPPE, while the pre-
vious research concentrates on either self-medication or
prescriptive drugs. Econometrically, our study is most sim-
ilar to the studies of [20, 22]. The results of our study are to
some extent in line with the previous literature [19, 20, 23–
25]. We confirm the effect of age on OTC pharmaceuticals
and prescription drugs and the mixed results for income. In
line with [23, 25], we find a positive effect of education on
the consumption of OTC pharmaceuticals. In contrast to
previous findings, we do not find an effect of private health
insurance on the probability and level of OOPPE. The same
is true for the type of public insurance. This is an indication
that public coverage against the risk of pharmaceutical
expenditures in Austria is high and homogenous. In line with
the majority of the previous research—an exemption is
[21]—we do not test for the price elasticity of pharmaceu-
tical consumption directly, but control for the existence of
different forms of insurance coverage.
We conclude our discussion section by pointing to
possible limitations of our study. In our presentation of the
empirical design of the study, we already pointed to several
challenges. In line with [19–21, 23, 24], we do not apply a
theoretical model of pharmaceutical consumption, but test
reduced forms. This means that our study to some extent
has an explanatory character. Our data picture the level of
households. This allows us to test for household charac-
teristics, e.g., the household structure. But we should be
aware of the fact that conclusions from the household level
to the individual level should be drawn with caution.
Although the decision to consume pharmaceuticals might
be influenced by household characteristics, it remains an
individual decision and mainly depends on individual
characteristics, which are masked to some extent on the
household level. This has important consequences for the
reproduction of the decision-making process when con-
suming pharmaceuticals. Additionally, the covariates age
and education have a different meaning on the household
level compared to the individual level, which might lead to
differences in the estimated effects. Finally, we want to
discuss the suitability of data from general consumption
surveys to picture the consumption of health care goods
and to identify the covariates driving the consumption level
and structure. General consumption surveys are well-
established instruments of economic accounting and follow
internationally agreed standards of reporting. This in
principle qualifies them as an information source also for
the consumption of health care goods and services. For
several reasons, general consumption surveys offer high
data quality concerning consumption expenditures and
selected socioeconomic characteristics of the households.
On the other hand, they only include rudimental informa-
tion on socioeconomic characteristics of individuals
(households) that are able to explain the utilization of
health care services, e.g., the consumption of pharmaceu-
ticals. Such characteristics are indicators for the health
status, the need of long-term care and the individual dis-
ease profile over a longer time period. The empirical lit-
erature clearly reveals that the health status—e.g.,
measured by health expenditure in the past—is an impor-
tant predictor of health-care expenditures and explains
most of the variance in regression models. The missing of
such information is an important source of unobserved
heterogeneity and is also an indication for the low
explanatory power of the used covariates in our estima-
tions. The explanatory power of the covariates used in the
previous literature, which controls for the health status—
see especially [19, 20, 22, 25], is substantially higher
compared to our results. In addition, general consumption
surveys normally do not include information on the supply
characteristics of health-care services (e.g., distribution of
pharmacies and physicians, provision/utilization of public
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health care services), which might influence the utilization
decision heavily. Finally, the information from consump-
tion surveys is period based and does not allow a separation
in different steps of the utilization process. Overall, we
conclude that the information on health expenditures (e.g.,
pharmaceutical expenditures) from consumption surveys
primarily should be used to study the covariates of phar-
maceutical consumption/expenditure from a distributive
point of view. They allow clear insights into the role of the
household structure (life cycle of the household), the
income and education in pharmaceutical consumption.
Conclusions
This article analyzes the socioeconomic determinants of
OOPPE of private households in Austria using data from
the household budget survey 2009/2010. Empirically, the
data show substantial differences in the expenditures
between households in different stages of their lifecycle.
The characteristics of the data set (information from the
household level, specification of the dependent variable,
period based instead of illness episode based data, short
observation period) pose several challenges to the choice of
the estimation strategy. The advantages of the widely used
TPM are no longer obvious. We react to this fact and
compare and use different econometric approaches (TPM,
GLM, Hurdle model, ZINB). Overall, we find that several
household characteristics—especially the household
structure, adults’ age, income, doctoral visits and adults’
education level—have strong effects on the probability and
level of OOPPE. This is especially true for OTC pharma-
ceuticals, but to a reduced degree also for prescription fees.
On the other hand, we do not find substantial effects of the
type of public health insurance and the existence of private
health insurance. The results of our study complete the
picture of the covariates of OOPPE on the individual with
evidence from the perspective of the household. The pre-
sent study can help health policy decision makers to
identify inequalities in pharmaceutical consumption and
obtain insights into the covariates causing them.
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Table 4 Overview of the used variable specification and the corresponding percentage of observations




Single person I 12.98 0.44 Household consists of one adult, single
Single person II 16.80 0.49 Household consists of one adult, either married, divorced or widowed
Unmarried couple 5.93 0.31 Household consists of two adults, unmarried
Married couple 10.13 0.40 Household consists of two adults, married, members are below 60 years
Empty nest 13.98 0.46 Household consists of two adults, married, members are above 60 years
Full nest I 12.37 0.43 Household consists of two adults, members are below 40 years, at least one
child
Full nest II 13.36 0.45 Household consists of two adults, members are above 40 years, at least one
child
Married couple w/o childs 6.22 0.32 Household consists of more than three adults, married, no children
Single parents 7.97 0.36 Household consists of one adult, at least one child
Degree of urbanization
High urbanization 35.65 0.63 Areas with a population of at least 50,000 and more than 500 inhabitants per
square kilometer
Average urbanization 25.90 0.58 Areas with a population of at least 50,000 and 100–500 inhabitants per
square kilometer
Low urbanization 38.45 0.64 All other areas
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